Analyst Price Targets — ABOS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 25, 2024 4:15 pm | David Hoang | Citigroup | $7.00 | $3.41 | TheFly | Acumen initiated with a Buy at Citi |
Latest News for ABOS
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the four analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABOS.
U.S. House Trading
No House trades found for ABOS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.